^(125)碘粒子植入术联合内分泌疗法治疗前列腺癌效果研究  

Clinical effect of combination of ^(125)I brachytherapy and endocrinotherapy on prostate cancer

作　　者：黄海锋[1] 汪维[1] 郭宏骞[1] 李笑弓[1] 张古田[1] 张士伟[1] 张帆[1] 

机构地区：[1]南京大学医学院附属鼓楼医院泌尿外科,江苏省南京市210008

出　　处：《实用老年医学》2014年第10期839-841,共3页Practical Geriatrics

摘　　要：目的初步评价125碘(125I)粒子植入术联合内分泌疗法治疗前列腺癌的临床疗效。方法选择2003年1月至2013年5月在我院就诊的51例前列腺癌患者,采用术中经直肠超声引导及治疗计划系统软件经会阴穿刺植入125I粒子并联合内分泌疗法治疗,观察临床效果。结果所有患者手术过程顺利。术后随访14~94月,术后尿道不适反应5例,远期(>1年)手术并发症轻度血便发生率为3.9%(2/51)。51例患者前列腺体积及前列腺特异抗原(PSA)均有不同程度降低。1例在术后34月死亡,有7例在术后平均16.7月出现PSA生化复发,累计PSA无进展生存率为84.3%。结论运用125I粒子植入术联合内分泌疗法治疗前列腺癌,患者长期并发症少,临床效果良好。Objective To evaluate the clinical efficacy of125 I brachytherapy combined with endocrinotherapy on prostate cancer. Methods Fifty-one patients with prostate cancer were treated with intraoperative125 I brachytherapy implanted through perineum under B-ultrasound and system therapy soft guidance and then combined with castration with operation or medicine. Results Therapeutic success was achieved in all patients. Follow-up ranged from 14-82 months. Five cases presented with urinary complications. The incidence rate of long term complications（ 1 year） such as mild bloody stools was 3. 9%（ 2 /34）. All patients were found that the level of PSA was reduced. One case died in 34 months post-operation. Seven cases had biochemical progression at an average of 16. 7 months post-operation. Cumulative PSA progression free survival rate was 84. 3%. Conclusions Combination of125 I brachytherapy and endocrinotherapy is an effective treatment method for prostate cancer only with a few complications.

关 键 词：前列腺癌 125碘粒子植入术 内分泌疗法 

分 类 号：R737.25[医药卫生—肿瘤]